版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Pharmacology
Whatis
efferentnervoussystem(ENS)?
pharmacologyofefferentnervoussystemceptoreffectorCNSANSENS(2)Motornervoussystem
pharmacologyofENSSection1structureandfunctionClassificationofanatomy(1)Autonomicnervoussystem
Sympatheticnerveparasympatheticnerve突触间隙Synapticcleftsynapse
pharmacologyofENSSection2transmitterandreceptortransmitters(1)Noradrenaline(NA)Norepinephrin(NE)TransmittersSynthesis,releasingandeliminationofNAsynthesisreleasingelimination12NANA(2)Acetylcholine(Ach)
pharmacologyofENSSection2transmitterandreceptortransmittersAChEAChSynthesis,releasingandeliminationofAChsynthesisreleasingelimination(2)adrenoceptors
αreceptor:α1andα2βreceptor:β1、β2andβ3
pharmacologyofENSSection2transmitterandreceptorreceptors(1)cholinceptorsMuscarinereceptor(MR):M1andM2Nicotinereceptor
(NR):N1and
N2(3)dopaminereceptors:D1andD2(2)noradrenergicnerve(adrenergicnerve)
pharmacologyofENSSection2transmitterandreceptorClassificationoftransmitters(1)cholinergicnerveACh
pharmacologyofENSSection3biologicaleffectandmechanism
biologicaleffectofENS
pharmacologyofENSSection3biologicaleffectandmechanismmolecularmechanismof
biologicaleffect
Ligandgatedionchannelreceptor,regulateNa+、K+、Ca2+flux.G-protein-coupledreceptors)drugactionandsignaitransduction
pharmacologyofENSSection4
actionmannersandclassificationofdrugsactionmanners(1)Direct:(2)Indirect:agonist
antagonistaffectreleaseaffecttransportandstorage
pharmacologyofENSSection4
actionmannersandclassificationofdrugsclassificationofdrugsacetylcholineChapter6cholinoceptoragonists
andcholinesteraseinhibitingdrugsSection1
cholinoceptoragonists
1.M、N-cholinoceptoragonistscarbaylcholine2.N-cholinoceptoragonistsnicotinepilocarpineChapter6cholinoceptoragonists
andcholinesteraseinhibitingdrugsSection1
cholinoceptoragonists
3.M-cholinoceptoragonistsstimulatesM-receptor3、M-cholinoceptoragonistspilocarpine1.EyePharmacologiceffects3.M-cholinoceptoragonistspilocarpine1.eyea.miosis(constrictpupil)
b.decreaseintraocularpressurec.cyclospasm(spasmofaccommodation)M
circularmuscleradialmuscle3、M-cholinoceptoragonistspilocarpine1.eye2.glands
increasesecretionofsweatglandandsalivarygland3.smoothmuscle3.M-cholinoceptoragonistspilocarpine1.glaucomaclinicalusesopen-angleglaucomaclose-angleglaucoma
2.iritiscorneaciliarymuscleiriscanalschlemnsuspensoryligamentslensChapter6cholinoceptoragonists
andcholinesteraseinhibitingdrugsSection2
cholinesteraseinhibitorsreversiblecholinesteraseinhibitorsnon-reversiblecholinesteraseinhibitorsneostigminephysostigmineorganophosphatesChapter6cholinoceptoragonists
andcholinesteraseinhibitingdrugsSection2
cholinesteraseinhibitorshydrolysisofAChAchAChEcholineaceticaciddrugsneostigmineChapter6cholinoceptoragonists
andcholinesteraseinhibitingdrugsSection2
cholinesteraseinhibitorsreversibleinhibitAChEreversiblecholinesteraseinhibitorsAchM-receptorN-receptorreversiblecholinesteraseinhibitors
neostigmine1.contractingskeletalmuscle
Pharmacologiceffectsverystrong--directactivatingN2receptors--releaseAchatthemotornerveendings2.stimulatingGItractandgallbladdersmoothmuscle
reversiblecholinesteraseinhibitors
neostigmine1.myastheniagravisclinical
uses2.postoperativeileusandurinaryretentioncholinergiccrisis3.paroxysmalsupraventriculartachycardia
4.overdosageofmusclerelaxantsreversiblecholiesteraseinhibitors
neostigminelargedosageAdverse
drugreactionnauseacholinergiccrisisvomitingabdominalpainmusclethrillorparalysisreversiblecholinesteraseinhibitors
neostigminemechanicalintestinalobstructioncontraindicationsurinaryobstructionbronchialasthmareversiblecholinesteraseinhibitorsphysostigmineeyea.miosisb.decreaseintraocularpressurec.CyclospasmreversiblecholinesteraseinhibitorsgalanthaminetensilontacrinedonepezilChapter7cholinoceptorantagonists1.M-cholinoceptorantagonists2.N1-cholinoceptorantagonists3.N2-cholinoceptorantagonistsdepolarizingdrugsnondepolarizingdrugssuccinylcholinetubocurarineM-cholinoceptorantagonists
atropinePharmacologic
effects1.
inhibitingthesecretionofgland
salivaryglandsweatglandbronchialsecretaryglandstomachglandM-cholinoceptorantagonists
atropinePharmacologiceffects2.
relaxingvisceralsmoothmuscle
stomachintestinedetrusorofbladderurinarytractbronchialmusclebiliarytractuterusM-cholinoceptorantagonists
atropinePharmacologiceffects3.
eye
mydriasisincreasesintraocularpressurecycloplegiaM
circularmuscleRadialmuscleM-cholinoceptorantagonists
atropinePharmacologiceffects4.
heart
smalldose:
---
decreasesheartrate
largedose:---
increasestheheartrate
M-cholinoceptorantagonists
atropinePharmacologiceffects5.
dilatingbloodvesselsandimprovemicrocirculation
therapeuticdose:
---nosignificanteffect
largedose:
---
dilatingbloodvessels
M-cholinoceptorantagonists
atropinePharmacologiceffects6.
CNS
therapeuticdose(0.5~1.0mg)
maximaldose
(1.0~2.0mg)
morelargedose
(2.0~5.0mg)
toxicdose(over10mg)
M-cholinoceptorantagonists
atropineclinicaluses1.
relievingspasmofsmoothmuscle
---visceralcolicpaingastricandintestinalcolicpainbladderirritatingsymptomsgallbladdercolicpain
renalcolicpain
M-cholinoceptorantagonists
atropineclinicaluses2.
inhibitingsecretionofglandpreanaestheticmedicationforcontrollingthesideeffectofetherseverenightsweatandslavers
adjunctivetherapyforpepticulcers
M-cholinoceptorantagonists
atropineclinicaluses3.
ophthalmologyiridocyclitisexaminingeyeground
examiningeyesight
M-cholinoceptorantagonists
atropineclinicaluses4.
cardiovasculardisorderslowtypearrhythmia
---bradycardia,S-Ablock,A-Vblock
---Adams-StokessyndromeinducedbyantimonyintoxicationM-cholinoceptorantagonists
atropineclinicaluses5.
antishock6.organophosphateintoxicationM-cholinoceptorantagonists
atropineAdversedrugreactioncontraindicationsglaucoma
pyloricobstructionprostatichypertrophyusewithcautionoldpeopleM-cholinoceptorantagonistsAnisodamine(654-2)scopolamineChapter8Adrenoceptor-activatingdrugscatecholCatecholamines,CAAdrenoceptor-activatingdrugs1.α-receptoragonists2.α、β-receptoragonists3.β-receptoragonists4.dopaminereceptoragonistsNoradrenaline,MetaraminolAdrenaline,EphedrineIsoprenaline,Dobutamine,SalbutamolDopamineα、β-adrenoceptoragonists
AdrenalineAdr,EpinephrinePharmacologic
effects1.
stimulatingtheheartcontractionforceheartrateconductionCO2.
contractandrelaxblood
vessels
skin,mucousmembranes--constrictionsplanchnicvessels
renalandmesenteric--constriction
cerebralandpulmonary--weakconstriction
skeletalmuscle--dilatationcoronaryarteryvessels
--dilatation3.
Bloodpressure
(1)systolicbloodpressure(2)diastolicbloodpressure
smalldose
↓=
largerdose
4.
relaxationofbronchialsmoothmuscle
5.
metaboliceffects
-increasemetabolism-energy-increaseinsulinsecretion-increaseoxygenconsumption
1.Cardiacarrest2.Allergicshock
3.Bronchialasthma
4.
Localapplication
clinicaluses◆hypertension◆sclerosisofcerebralartery◆ischemicheartdisease◆congestiveheartfailure◆
hyperthyrea◆diabetesAdversedrugreactioncontraindicationsEphedrinePharmacologic
effects---similartoadrenaline---actionisweakandlonger---enhancesthereleaseofNA
---centralactions---preventhypotension---bronchial
asthma---nasalcongestion---allergyclinicalusesDopaminePharmacokinetics---precursorofNAandAdr---metabolizedbyCOMTandMAO---enhancesthereleaseofNA---noeffectwithP.O.(ivggt)---noeffectonCNS(notpenetrateBBB)Pharmacologic
effectslowdose(1)increasecardiaccontractility--β1+NAreleaseSBP(2)vasoconstriction(α1)DBP=vasodilation(D1)(3)increaseinglomerularfiltrationrate,renalbloodflowandNa+excretion(D1)
largedoseα1>D1(1)sometypesofshock
---cardiogenic,septicshockandhemorrhagicshockespeciallywithcardiacdysfunction,oliguriaoranuria(2)acuterenalinsufficiency---withdiuretics(3)congestiveheartfailureclinicalusesα-adrenoceptoragonistsNoradrenalineNA,NorepinephrinePharmacologic
effects1.
stimulatingtheheart
2.
contractblood
vessels
3.
increasingbloodpressure1.Hypotension2.earlyphaseofneurogenicshock
3.uppergastrointestinaltract
bleeding
clinicaluses
▲
hypertension
▲
atherosclerosis
▲
coronaryheartdisease
▲
oliguriaandanuriaAdversedrugreactioncontraindicationsMetaraminolPharmacologic
effects---actsonα1receptor
---causesNArelease---increasesBPandcardiacoutput---decreasesheartrate
β
-adrenoceptoragonists
Isoprenaline,IsoproterenolPharmacologic
effects1.
stimulatingtheheart2.
relaxblood
vessels3.
decreasingbloodpressure4.
relaxationofbronchialsmoothmuscle
5.
metaboliceffects1.bronchial
asthma2.cardiacarrest3.Atrio–ventricularconductionblock
4.shock
clinicaluses
■
coronaryheartdisease
■
myocarditis
■
hyperthyroidismAdversedrugreactioncontraindications
NAAdrIsoDA
minPeripheralresistanceArterialpressurePR拟肾上腺素药基本作用的比较α1、α2-receptoragonists
Phentolamine,Tolazoline,Phenoxybenzamineα1-receptoragonistsPrazosin,Dorazosin,TerazosinChapter9AdrenoceptorBlockingDrugsS1.α-receptorantagonistsS2.β-receptorantagonistsβ1、β2-receptoragonists
Propranolol,Timolol,Pindololβ1-receptoragonistsAtenolol,Metoprolol,AcebutololS1.α-receptorantagonists
★blockα–receptor,antagonizetheeffectsofα-agonists
★afterpretreatmentwithα-antagonist--AdrshowsdecreaseBP
–called“epinephrinereversal”
α1、α2-receptorantagonistsPhentolaminePharmacologic
effects1.reducesperipheralresistance--blockα1
--relaxblood
vessels2.cardiacstimulation
--reflexcardiacmechanisms--blockspresynapticα2
enhancedNArelease3.M,H1,H2agonist1.peripheralvascularspasmdiseases2.localvasoconstrictor--NAi.v3.anti-shock4.stub
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年软件开发源代码托管合同协议
- GB 175-2023《通 用硅酸盐水泥》变化
- 无伤运动-预防与康复的关键策略
- 房产中介:开启市场新篇章-破局竞争拥抱变革与机遇
- 期货投资:智慧资产配置-解读市场掌控风险增值收益
- 学科兴趣分享-分享学科兴趣与成果
- 智慧房产:团队协作之道-深化项目管理提升交付效率
- 2026七年级数学上册 字母表示数
- 科研技能教程单元课01onine数据库使用教程
- UX设计培训试题及答案
- 山东省青岛市西海岸新区达标名校2026届中考数学最后一模试卷含解析
- 2025-2026学年四川省德阳市中考物理模拟试题(含答案解析)
- 《劳动创造美好生活(第二版)》课件 幸福不会从天而降
- (正式版)DB37∕T 4976-2025 《河湖生态产品价值核算技术规范》
- 【答案】《戏剧艺术概论》(中央戏剧学院)章节作业慕课答案
- 重度颅脑损伤的急救与护理
- 恒丰银行招聘真题及答案
- GB/T 11918.1-2025工业用插头、固定式或移动式插座和器具输入插座第1部分:通用要求
- 小区改造施工脚手架施工方案
- 事业单位A类综合应用能力试题答案
- 2025至2030年中国短肽型肠内营养制剂行业竞争格局分析及投资发展研究报告
评论
0/150
提交评论